Sfikakis, Petros P. http://orcid.org/0000-0001-5484-2930
Vassilopoulos, Dimitrios
Katsifis, Gkikas
Vosvotekas, Georgios
Dimitroulas, Theodoros
Sidiropoulos, Prodromos
Vounotrypidis, Periklis
Bogdanos, Dimitrios P.
Georgountzos, Athanasios Ι.
Bounas, Andreas G.
Georgiou, Panagiotis
Gazi, Souzana
Kataxaki, Evangelia
Liossis, Stamatis-Nick
Theodorou, Evangelos
Papagoras, Charalampos
Theotikos, Evangelos
Vlachoyiannopoulos, Panayiotis
Voulgari, Paraskevi V.
Kekki, Angeliki
Antonakopoulos, Nikolaos
Boumpas, Dimitrios T.
Funding for this research was provided by:
Genesis Pharma
Celgene
University of Athens
Article History
Received: 19 October 2022
Accepted: 29 December 2022
First Online: 1 March 2023
Declarations
:
: PPS has received consultant fees from Actelion, Pfizer, Genesis, MSD, UCB, Boehringer Ingelheim, Aenorasis, Farmaserv Lilly, Gilead, Abbvie, and Novartis, and grant/research support from Abbvie, Roche, Pfizer, Faran, Amgen, Jannsen, Boehringer Ingelheim, and Gilead. DV was a sub-PI of the study sponsored by Genesis. GK has received honoraria for educational activities and consultancy payments from Abbvie, Aenorasis, Amgen, Celgene, Genesis Pharma, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sobi, and Vianex. GV has received investigator and consultant fees from Genesis Pharma. TD has served as a speaker and consultant and has received investigator honoraria and travel fees from Genesis Pharma and Abbvie, has served as a speaker and consultant and has received investigator honoraria from Lilly, has served as a speaker, consultant, and has received investigator honoraria and travel fees from Novartis, has served as a speaker, consultant, and has received travel fees from Pfizer, has served as a speaker, consultant, and has received investigator honoraria and travel fees from Janssen and UCB, has served as a consultant and has received investigator honoraria and travel fees from Elpen, has served as a speaker and consultant for Boehringer Ingelheim, has served as a speaker and consultant, and has received travel fees from Mylan, has served as a consultant for Amgen, has received investigator honoraria from Demo, has received travel fees from MSD, has served as a speaker and consultant, and has received travel fees from Aenorasis, and travel fees from Faran. PS has received research grants, consultation fees and speaker honoraria through the “Univesity of Crete Special Account for Research”. PV has received investigator fees from Abbvie, Novartis and Genesis Pharma, and travel fees from Viatris, Abbvie and Boehringer Ingelheim. DPB has received lecture honoraria from Menarini Hellas, Boehringer Ingelheim, Genesis Pharma, and Fresenius Kabi, lecture honoraria, hospital line travel fees and accommodation support from Novartis, travel fees and accommodation support from Pfizer, Elpen, Aenorasis Hellas, Novartis, and IFT Hellas, and grant support for research and educational activities from Elpen, Boehringer Ingelheim, Demo, and Menarini Hellas. AIG has received investigator and consultant fees from AbbVie, investigator fees from Genesis Pharma and Janssen Pharmaceuticals, speaker fees from Mylan, consultant fees from UCB, and speaker fees from Boehringer Ingelheim and Roche Hellas. AGB has served as speaker/consultant for Abbvie, Aenorasis, Amgen, Bausch Health, FARAN, Genesis Pharma, GSK, Janssen, MSD, Novartis, Pfizer, UCB, and has received grant/research support from Abbvie, Amgen, Genesis, MSD, Novartis, Pfizer. PG has received investigator honoraria and consultant fees from UCB, Genesis Pharma, Abbvie, Mylan, Aenorasis Jannsen Cilag. SG has received speaker and travel fees from Eli Lilly, investigator, speaker and travel fees from Abbvie, travel fees in congress from Jannsen, consultant and speaker honoraria from Boehringer Ingelheim, investigator fees from Genesis Pharma, investigator honoraria from Mylan, Elpen, Aenorasis, and registration in congress from Novartis. EK has received investigator fees from Genesis Pharma and Mylan. SNL has no conflicts of interest. ET has received speaker and consultant fees from Amgen, investigator, speaker and consultant fees from Abbvie, consultant fees from Aenorasis, consultant and travel fees from Faran, speaker fees from Lilly, speaker and investigator fees from Pfizer, and consultant fees and investigator fees (PhD grant) from GSK. CP has served as speaker for Abbvie, Genesis, Lilly, Pfizer, UCB, and Boehringer-Ingelheim, consultant for Lilly, Genesis, Pfizer, and Janssen, and has received grant/research support from Lilly, Faran, Elpen, and Demo. ET has no conflict of interest. PV has no conflict of interest. PVV has received consultant fees from UCB, Gilead Sciences Hellas, Novartis, Abbvie, Pfizer, Janssen Gilag, Glaxo Smith Kline, and Amgen. AK is an employee of Genesis Pharma. NA is an employee of Genesis Pharma. DTB has received an educational grant to the University research Account.
: The study was reviewed and approved by the competent Institutional Review Boards of all participating hospital sites (study code: ΝIS-GEN-APR-002). All patients provided written informed consent.
: Not applicable.